A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
NCT02753309
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Bladder Cancer
Interventions
DRUG:
Sirolimus
Sponsor
The University of Texas Health Science Center at San Antonio